Versartis Company Profile (NASDAQ:VSAR)

About Versartis

Versartis logoVersartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's product pipeline includes VRS-317 and XTEN Technology. The Company's VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company's XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VSAR
  • CUSIP:
Key Metrics:
  • Previous Close: $11.85
  • 50 Day Moving Average: $12.47
  • 200 Day Moving Average: $11.01
  • 52-Week Range: $6.17 - $14.69
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.00
  • P/E Growth: 0.00
  • Market Cap: $350.06M
  • Outstanding Shares: 29,541,000
  • Beta: 2.2
  • Return on Equity: -52.55%
  • Return on Assets: -49.94%
  • Current Ratio: 16.99%
  • Quick Ratio: 16.99%
Additional Links:
Companies Related to Versartis:

Analyst Ratings

Consensus Ratings for Versartis (NASDAQ:VSAR) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $21.00 (77.22% upside)

Analysts' Ratings History for Versartis (NASDAQ:VSAR)
DateFirmActionRatingPrice TargetDetails
10/4/2016Piper Jaffray Cos.Initiated CoverageOverweight$22.00View Rating Details
9/27/2016Canaccord GenuityReiterated RatingBuy$28.00View Rating Details
9/19/2016Credit Suisse Group AGReiterated RatingSell$11.00View Rating Details
8/11/2016Citigroup Inc.Set Price TargetBuy$17.00 -> $23.00View Rating Details
4/30/2016Morgan StanleyReiterated RatingHoldView Rating Details
4/7/2016Northland SecuritiesInitiated CoverageOutperformView Rating Details
2/2/2016Cowen and CompanyReiterated RatingBuyView Rating Details
5/10/2015SunTrust Banks Inc.Reiterated RatingBuy$50.00 -> $45.00View Rating Details
(Data available from 10/28/2014 forward)


Earnings History for Versartis (NASDAQ:VSAR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016Q2($0.78)($0.75)ViewN/AView Earnings Details
2/18/2016Q415($0.71)($0.69)ViewN/AView Earnings Details
10/29/2015Q3($0.79)($0.69)ViewN/AView Earnings Details
8/4/2015Q2($0.64)($0.67)ViewN/AView Earnings Details
5/6/2015($0.70)($0.79)ViewN/AView Earnings Details
2/12/2015Q414($0.53)($0.65)ViewN/AView Earnings Details
11/6/2014Q3 14($0.46)($0.57)ViewN/AView Earnings Details
5/5/2014Q114($6.37)($2.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Versartis (NASDAQ:VSAR)
Current Year EPS Consensus Estimate: $-3.14 EPS
Next Year EPS Consensus Estimate: $-2.37 EPS


Dividend History for Versartis (NASDAQ:VSAR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Versartis (NASDAQ:VSAR)
Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 59.28%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2016Srinivas AkkarajuDirectorBuy571,429$12.25$7,000,005.25View SEC Filing  
8/25/2016John VarianDirectorSell1,600$12.97$20,752.00View SEC Filing  
8/22/2016Jay ShepardCEOSell5,442$12.88$70,092.96View SEC Filing  
6/15/2016Joshua T BrummCFOSell1,448$10.63$15,392.24View SEC Filing  
6/15/2016Paul WestbergVPSell725$10.63$7,706.75View SEC Filing  
5/20/2016Joshua T BrummCFOSell1,265$7.87$9,955.55View SEC Filing  
4/21/2016Paul WestbergVPSell1,430$9.68$13,842.40View SEC Filing  
12/30/2015Joshua T BrummCFOSell990$12.44$12,315.60View SEC Filing  
12/30/2015Paul WestbergVPSell362$12.44$4,503.28View SEC Filing  
11/12/2015Joshua T BrummCFOBuy2,500$9.99$24,975.00View SEC Filing  
11/11/2015R Scott GreerDirectorBuy10,000$10.17$101,700.00View SEC Filing  
7/6/2015Paul WestbergVPSell2,400$15.00$36,000.00View SEC Filing  
6/3/2015Paul WestbergVPSell2,400$16.73$40,152.00View SEC Filing  
5/4/2015Paul WestbergVPSell2,400$17.47$41,928.00View SEC Filing  
4/14/2015Jeffrey L ClelandCEOSell8,000$20.13$161,040.00View SEC Filing  
4/6/2015Paul WestbergVPSell2,400$17.49$41,976.00View SEC Filing  
3/23/2015Jeffrey L ClelandCEOSell4,000$20.26$81,040.00View SEC Filing  
3/20/2015Jeffrey L ClelandCEOSell3,179$20.03$63,675.37View SEC Filing  
3/10/2015Jeffrey L ClelandCEOSell4,000$20.23$80,920.00View SEC Filing  
3/2/2015Jeffrey L ClelandCEOSell2,871$20.11$57,735.81View SEC Filing  
2/3/2015Paul WestbergVPSell5,000$17.40$87,000.00View SEC Filing  
1/27/2015Aisling Capital Iii LpMajor ShareholderBuy145,000$17.25$2,501,250.00View SEC Filing  
1/27/2015R Scott GreerDirectorBuy5,500$17.25$94,875.00View SEC Filing  
1/22/2015Shahzad MalikDirectorBuy55,000$17.25$948,750.00View SEC Filing  
1/12/2015Jeffrey L ClelandCEOSell4,000$22.85$91,400.00View SEC Filing  
1/5/2015Jeffrey L ClelandCEOSell4,000$21.94$87,760.00View SEC Filing  
1/5/2015Paul WestbergVPSell5,000$22.48$112,400.00View SEC Filing  
12/29/2014Jeffrey L ClelandCEOSell4,000$22.11$88,440.00View SEC Filing  
12/22/2014Jeffrey L ClelandCEOSell8,000$21.14$169,120.00View SEC Filing  
12/18/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell150,000$19.01$2,851,500.00View SEC Filing  
12/12/2014Paul WestbergVPSell10,000$18.55$185,500.00View SEC Filing  
11/24/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell17,207$18.02$310,070.14View SEC Filing  
11/21/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell26,793$18.04$483,345.72View SEC Filing  
11/20/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell9,000$18.32$164,880.00View SEC Filing  
11/18/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell191,362$19.38$3,708,595.56View SEC Filing  
11/13/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell12,438$19.43$241,670.34View SEC Filing  
11/12/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell36,200$19.42$703,004.00View SEC Filing  
9/29/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell12,556$20.02$251,371.12View SEC Filing  
3/27/2014Leaf Ventures Ii L.P. NewDirectorBuy60,000$21.02$1,261,200.00View SEC Filing  
3/26/2014Aisling Capital Iii LpMajor ShareholderBuy60,000$21.00$1,260,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Versartis (NASDAQ:VSAR)
DateHeadline logoPhase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN® Technology (NASDAQ:VSAR) - October 17 at 7:53 PM logoVersartis : Phase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN(R) Technology (NASDAQ:VSAR) - October 17 at 7:53 PM logoVersartis (VSAR) Approves to Commence Somavaratan Phase 3 in Japan (NASDAQ:VSAR) - October 17 at 7:53 PM logoPhase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN(R) Technology (NASDAQ:VSAR) - October 17 at 7:53 PM logoVERSARTIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:VSAR) - October 14 at 7:51 PM
News IconVersartis Inc. (VSAR): Perceptive Advisors Raises Stake (NASDAQ:VSAR) - October 6 at 1:51 PM logoCoverage initiated on Versartis by Piper Jaffray (NASDAQ:VSAR) - October 4 at 7:28 PM logoVersartis (VSAR) Prices 4.9M Offering of Common Stock at $12.25/Share (NASDAQ:VSAR) - September 29 at 7:54 PM logoVersartis : Announces Pricing of Follow-On Offering (NASDAQ:VSAR) - September 29 at 7:54 PM logoVersartis Announces Proposed Offering of Common Stock (NASDAQ:VSAR) - September 27 at 7:56 PM logoVersartis Initiates Phase 3 Trial of Somavaratan in Japan for Children with Growth Hormone Deficiency Following Completion of Phase 2 (NASDAQ:VSAR) - September 26 at 8:13 AM logoVERSARTIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:VSAR) - September 15 at 11:47 AM logoVersartis, Inc. :VSAR-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 (NASDAQ:VSAR) - September 14 at 12:23 PM logoVersartis Presents Data From Up to 30 Months of Somavaratan Treatment for Pediatric Growth Hormone Deficiency at the 2016 ESPE Annual Meeting (NASDAQ:VSAR) - September 12 at 7:31 PM
News Icon1} Presents Efficacy, Safety, Metabolic And Adherence Data For Somavaratan In Oral Session At The International Congress Of Endocrinology (NASDAQ:VSAR) - September 6 at 8:06 PM logoVersartis to Present at the Morgan Stanley Global Healthcare Conference (NASDAQ:VSAR) - September 6 at 8:06 PM logoVersartis to Host Investor Symposium Featuring Leading Experts in Growth Hormone Deficiency (NASDAQ:VSAR) - September 6 at 8:06 PM logoVersartis Presents Efficacy, Safety, Metabolic and Adherence Data for Somavaratan in Oral Session at the International Congress of Endocrinology (NASDAQ:VSAR) - September 3 at 6:59 PM logoVersartis (VSAR) Announces Presentation of Somavaratan Data at 17th ICE in Beijing (NASDAQ:VSAR) - September 3 at 6:59 PM logoLong Acting Growth Hormone Based on Amunix' XTEN(R) Technology Completes Enrollment of Phase 3 Trial (NASDAQ:VSAR) - September 2 at 8:31 AM logoVersartis : VSAR) Completes Enrollment in Phase III VELOCITY Trial of Somavaratan for the Treatment of Pediatric GHD (NASDAQ:VSAR) - August 27 at 7:13 AM logoNew Market Report: Versartis, Inc. (VSAR) - Financial and Strategic SWOT Analysis Review (NASDAQ:VSAR) - August 25 at 7:19 AM logoVersartis (VSAR) Completes Phase 3 VELOCITY Trial Enrollment (NASDAQ:VSAR) - August 22 at 8:05 PM logoVersartis Inc.: Teijin Limited and Versartis Enter Strategic Alliance for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan (NASDAQ:VSAR) - August 10 at 11:26 AM logoVersartis (VSAR), Teijin Enter Strategic Alliance for Somavaratan in Japan (NASDAQ:VSAR) - August 10 at 11:26 AM logoTeijin Limited and Versartis Enter Strategic Alliance for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan (NASDAQ:VSAR) - August 9 at 8:32 PM logoVersartis to Present at the Canaccord Genuity 36th Annual Growth Conference (NASDAQ:VSAR) - August 4 at 11:28 AM logoVersartis Reports Second Quarter 2016 Financial Results (NASDAQ:VSAR) - July 29 at 11:14 AM logoVersartis' Long-Acting Somavartan Could Replace Current Treatments In Growth Hormone Deficiency (NASDAQ:VSAR) - July 29 at 11:14 AM logoVersartis reports 2Q loss (NASDAQ:VSAR) - July 28 at 5:59 PM logoLpath (LPTN), Arcadia (RKDA), Helios (HMNY) Post Biggest Moves today (NASDAQ:VSAR) - June 14 at 6:37 AM logoVERSARTIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:VSAR) - June 3 at 6:09 AM logoVersartis, Inc. :VSAR-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 (NASDAQ:VSAR) - June 2 at 1:03 PM logoVersartis Inc (VSAR) is Trading Higher on Unusual Volume for May 23 - (NASDAQ:VSAR) - May 25 at 2:47 PM logoVersartis Inc (VSAR) Jumps 8.38% on May 23 - (NASDAQ:VSAR) - May 25 at 2:47 PM logoVERSARTIS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:VSAR) - May 23 at 4:03 PM logoVersartis Inc (VSAR) Jumps 5.89% on May 16 - (NASDAQ:VSAR) - May 19 at 2:32 PM logoVersartis Inc (VSAR) Jumps 5.69% on May 09 - (NASDAQ:VSAR) - May 11 at 8:30 AM
News IconVersartis Inc (VSAR) Receives “Buy” Rating from Canaccord Genuity - Washington News Wire (NASDAQ:VSAR) - May 11 at 8:30 AM
News IconLatest Analyst Ratings For Versartis, Inc. (NASDAQ:VSAR) - Share Trading News (NASDAQ:VSAR) - May 6 at 9:06 AM logoVersartis Inc (VSAR) Drops 6.37% on May 03 - (NASDAQ:VSAR) - May 6 at 9:06 AM logoVersartis Inc (VSAR) is Trading Lower on Unusual Volume for May 04 - (NASDAQ:VSAR) - May 6 at 9:06 AM
News IconHow Analysts Feel About Versartis Inc (NASDAQ:VSAR)? - B.O.D.Y Confidential (NASDAQ:VSAR) - May 4 at 7:41 AM logoVERSARTIS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:VSAR) - May 4 at 6:14 AM logoVersartis, Inc. (NASDAQ:VSAR) ABR of 1.67 - Investor Newswire (NASDAQ:VSAR) - May 1 at 8:51 AM logoVersartis reports 1Q loss (NASDAQ:VSAR) - April 28 at 6:29 PM logo4:56 pm Versartis reports Q1 EPS of ($0.82) vs. ($0.77) Capital IQ consensus (NASDAQ:VSAR) - April 28 at 4:56 PM logoVersartis Reports First Quarter 2016 Financial Results (NASDAQ:VSAR) - April 28 at 4:36 PM
News IconVersartis, Inc. (VSAR) Files Form 4 Insider Selling : Paul Westberg Sells 1430 Shares - Market Digest (NASDAQ:VSAR) - April 27 at 10:32 AM
News IconVersartis, Inc. (NASDAQ:VSAR) Latest Broker Views - Risers & Fallers (NASDAQ:VSAR) - April 27 at 10:32 AM


Versartis (NASDAQ:VSAR) Chart for Friday, October, 28, 2016

Last Updated on 10/28/2016 by Staff